Automated insulin delivery (AID) may benefit individuals with long-standing type 1 diabetes where frequent exposure to hypoglycemia impairs counterregulatory responses. This study assessed the effect of 18 months AID on hypoglycemia avoidance and glucose counterregulatory responses to insulin-induced hypoglycemia in long-standing type 1 diabetes complicated by impaired awareness of hypoglycemia.
Methods:
Ten participants mean ± standard deviation age 49 ± 16 and diabetes duration 34 ± 16 years were initiated on AID. Continuous glucose monitoring was paired with actigraphy to assess awake- and sleep-associated hypoglycemia exposure every 3 months. Hyperinsulinemic hypoglycemic clamp experiments were performed at baseline, 6, and 18 months postintervention. Hypoglycemia exposure was reduced by 3 months, especially during sleep, with effects sustained through 18 months (P ≤ 0.001) together with reduced glucose variability (P < 0.01).
Results:
Hypoglycemia awareness and severity scores improved (P < 0.01) with severe hypoglycemia events reduced from median (interquartile range) 3 (3–10) at baseline to 0 (0–1) events/person·year postintervention (P = 0.005). During the hypoglycemic clamp experiments, no change was seen in the endogenous glucose production (EGP) response, however, peripheral glucose utilization during hypoglycemia was reduced following intervention [pre: 4.6 ± 0.4, 6 months: 3.8 ± 0.5, 18 months: 3.4 ± 0.3 mg/(kg·min), P < 0.05]. There were increases over time in pancreatic polypeptide (Pre:62 ± 29, 6 months:127 ± 44, 18 months:176 ± 58 pmol/L, P < 0.01), epinephrine (Pre: 199 ± 53, 6 months: 332 ± 91, 18 months: 386 ± 95 pg/mL, P = 0.001), and autonomic symptom (Pre: 6 ± 2, 6 months: 6 ± 2, 18 months: 10 ± 2, P < 0.05) responses.
Conclusions:
AID led to a sustained reduction of hypoglycemia exposure. EGP in response to insulin-induced hypoglycemia remained defective, however, partial recovery of glucose counterregulation was evidenced by a reduction in peripheral glucose utilization likely mediated by increased epinephrine secretion and, together with improved autonomic symptoms, may contribute to the observed clinical reduction in hypoglycemia.
Get full access to this article
View all access options for this article.
References
1.
American Diabetes Association Professional Practice Committee, DrazninB, ArodaVR, et al.6. Glycemic targets: Standards of medical care in diabetes—2022. Diabetes Care, 2022; 45(Suppl 1):S83–S96.
2.
CryerPE. The barrier of hypoglycemia in diabetes. Diabetes, 2008; 57(12):3169–3176.
3.
RajuB, CryerPE. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes—Documentation of the intraislet insulin hypothesis in humans. Diabetes, 2005; 54(3):757–764.
4.
ArbelaezAM, XingD, CryerPE, et al.Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. Pediatr Diabetes, 2014; 15(2):127–134.
5.
HellerSR, CryerPE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes, 1991; 40(2):223–226.
6.
Dagogo-JackSE, CraftS, CryerPE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest, 1993; 91(3):819–828.
7.
CryerPE. Mechanisms of sympathoadrenal failure and hypoglycemia in diabetes. J Clin Invest, 2006; 116(6):1470–1473.
8.
MaY, WangQ, JoeD, et al.Recurrent hypoglycemia inhibits the counterregulatory response by suppressing adrenal activity. J Clin Invest, 2018; 128(9):3866–3871.
RickelsMR. Hypoglycemia-associated autonomic failure, counterregulatory responses, and therapeutic options in type 1 diabetes. Ann N Y Acad Sci, 2019; 1454(1):68–79.
11.
Pedersen-BjergaardU, PrammingS, HellerSR, et al.Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: Influence of risk markers and selection. Diabetes Metab Res Rev, 2004; 20(6):479–486.
12.
WeinstockRS, XingDY, MaahsDM, et al.Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: Results from the T1D Exchange clinic registry. J Clin Endocrinol Metab, 2013; 98(8):3411–3419.
13.
GagnumV, SteneLC, JenssenTG, et al.Causes of death in childhood-onset type 1 diabetes: Long-term follow-up. Diabet Med, 2017; 34(1):56–63.
14.
LacyME, GilsanzP, EngC, et al.Severe hypoglycemia and cognitive function in older adults with type 1 diabetes: The study of longevity in diabetes (SOLID). Diabetes Care, 2020; 43(3):541–548.
15.
FanelliCG, EpifanoL, RambottiAM, et al.Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes, 1993; 42(11):1683–1689.
16.
LeelarathnaL, LittleSA, WalkinshawE, et al.Restoration of self-awareness of hypoglycemia in adults with long-standing type 1 diabetes: Hyperinsulinemic-hypoglycemic clamp substudy results from the HypoCOMPaSS trial. Diabetes Care, 2013; 36(12):4063–4070.
17.
de ZoysaN, RogersH, StadlerM, et al.A psychoeducational program to restore hypoglycemia awareness: The DAFNE-HART pilot study. Diabetes Care, 2014; 37(3):863–866.
18.
LittleSA, LeelarathnaL, WalkinshawE, et al.Recovery of hypoglycemia awareness in long-standing type 1 diabetes: A multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care, 2014; 37(8):2114–2122.
19.
RickelsMR, PeleckisAJ, Dalton-BakesC, et al.Continuous glucose monitoring for hypoglycemia avoidance and glucose counterregulation in long-standing type 1 diabetes. J Clin Endocrinol Metab, 2018; 103(1):105–114.
20.
ChoudharyP, RamasamyS, GreenL, et al.Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes. Diabetes Care, 2013; 36(12):4160–4162.
21.
van BeersCA, DeVriesJH, KleijerSJ, et al.Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): A randomised, open-label, crossover trial. Lancet Diabetes Endocrinol, 2016; 4(11):893–902.
22.
HeinemannL, FreckmannG, EhrmannD, et al.Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): A multicentre, randomised controlled trial. Lancet, 2018; 391(10128):1367–1377.
23.
JonesTW, PorterP, SherwinRS, et al.Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med, 1998; 338(23):1657–1662.
24.
BanarerS, CryerPE. Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: Reduced awakening from sleep during hypoglycemia. Diabetes, 2003; 52(5):1195–1203.
25.
ZekariasK, KumarA, MoheetA, et al.Real life evidence that impaired awareness of hypoglycemia persists for years in patients with type 1 diabetes. J Diabetes Complications, 2018; 32(12):1097–1099.
26.
LinYK, HungM, SharmaA, et al.Impaired awareness of hypoglycemia continues to be a risk factor for severe hypoglycemia despite the use of continuous glucose monitoring system in type 1 diabetes. Endocr Pract, 2019; 25(6):517–525.
27.
InfanteM, BaidalDA, RickelsMR, et al.Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions. Artif Organs, 2021; 45(9):968–986.
28.
RuanY, BallyL, ThabitH, et al.Hypoglycaemia incidence and recovery during home use of hybrid closed-loop insulin delivery in adults with type 1 diabetes. Diabetes Obes Metab, 2018; 20(8):2004–2008.
29.
AkturkHK, GiordanoD, ChampakanathA, et al.Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab, 2020; 22(4):583–589.
30.
BrownSA, KovatchevBP, RaghinaruD, et al.Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med, 2019; 381(18):1707–1717.
31.
BosiE, ChoudharyP, de ValkHW, et al.Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): An open-label randomised controlled trial. Lancet Diabetes Endocrinol, 2019; 7(6):462–472.
32.
AndersonSM, BuckinghamBA, BretonMD, et al.Hybrid closed-loop control is safe and effective for people with T1D who are at moderate to high risk for hypoglycemia. Diabetes Technol Ther, 2019; 21:356–363.
33.
BurckhardtMA, AbrahamMB, DartJ, et al.Impact of hybrid closed loop therapy on hypoglycemia awareness in individuals with type 1 diabetes and impaired hypoglycemia awareness. Diabetes Technol Ther, 2021; 23(7):482–490.
34.
ClarkeWL, CoxDJ, Gonder-FrederickLA, et al.Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care, 1995; 18(4):517–522.
35.
RyanEA, ShandroT, GreenK, et al.Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes, 2004; 53(4):955–962.
36.
SeniorPA, BellinMD, AlejandroR, et al.Consistency of quantitative scores of hypoglycemia severity and glycemic lability and comparison with continuous glucose monitoring system measures in long-standing type 1 diabetes. Diabetes Technol Ther, 2015; 17(4):235–242.
37.
MaloneSK, PeleckisAJ, GruninL, et al.Characterizing glycemic control and sleep in adults with long-standing type 1 diabetes and hypoglycemia unawareness initiating hybrid closed loop insulin delivery. J Diabetes Res, 2021; 2021:6611064.
38.
RickelsMR, PeleckisAJ, MarkmannE, et al.Long-term improvement in glucose control and counterregulation by islet transplantation for type 1 diabetes. J Clin Endocrinol Metab, 2016; 101(11):4421–4430.
39.
FlattAJ, ChenE, PeleckisAJ, et al.Evaluation of clinical metrics for identifying defective physiologic responses to hypoglycemia in long-standing type 1 diabetes. Diabetes Technol Ther, 2022; 24(10):737–748.
40.
BernroiderE, BrehmA, KrssakM, et al.The role of intramyocellular lipids during hypoglycemia in patients with intensively treated type 1 diabetes. J Clin Endocrinol Metab, 2005; 90(10):5559–5565.
41.
TowlerDA, HavlinCE, CraftS, et al.Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes, 1993; 42(12):1791–1798.
42.
RickelsMR, FullerC, Dalton-BakesC, et al.Restoration of glucose counterregulation by islet transplantation in long-standing type 1 diabetes. Diabetes, 2015; 64(5):1713–1718.
43.
LanKK, WittesJ. The B-value: A tool for monitoring data. Biometrics, 1988; 44(2):579–585.
44.
MonnierL, WojtusciszynA, MolinariN, et al.Respective contributions of glycemic variability and mean daily glucose as predictors of hypoglycemia in type 1 diabetes: Are they equivalent?. Diabetes Care, 2020; 43(4):821–827.
45.
KovatchevBP, CoxDJ, Gonder-FrederickLA, et al.Assessment of risk for severe hypoglycemia among adults with IDDM: Validation of the low blood glucose index. Diabetes Care, 1998; 21(11):1870–1875.
46.
SepulvedaE, PoinhosR, NataG, et al.Differentiating hypoglycemia awareness status from hypoglycemia experience in tools for measuring impaired awareness of hypoglycemia. Diabetes Technol Ther, 2020; 22(7):541–545.
47.
CryerPE, GerichJE. Relevance of glucose counterregulatory systems to patients with diabetes: Critical roles of glucagon and epinephrine. Diabetes Care, 1983; 6(1):95–99.
48.
RizzaRA, CryerPE, GerichJE. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest, 1979; 64(1):62–71.
49.
BattelinoT, DanneT, BergenstalRM, et al.Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care, 2019; 42(8):1593–1603.
50.
Da SilvaJ, BosiE, JendleJ, et al.Real-world performance of the MiniMed 670G system in Europe. Diabetes Obes Metab, 2021; 23(8):1942–1949.
51.
RodbardD. Hypo- and hyperglycemia in relation to the mean, standard deviation, coefficient of variation, and nature of the glucose distribution. Diabetes Technol Ther, 2012; 14(10):868–876.
52.
ChoudharyP, RickelsMR, SeniorPA, et al.Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care, 2015; 38(6):1016–1029.
53.
BolliG, De FeoP, PerrielloG, et al.Role of hepatic autoregulation in defense against hypoglycemia in humans. J Clin Invest, 1985; 75(5):1623–1631.
54.
FritscheA, StefanN, HaringH, et al.Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann Intern Med, 2001; 134(9 Pt 1):729–736.
55.
DagogojackS, RattarasarnC, CryerPE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes, 1994; 43(12):1426–1434.
56.
DeRosaMA, CryerPE. Hypoglycemia and the sympathoadrenal system: Neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab, 2004; 287(1):E32–E41.
57.
WhiteNH, GingerichRL, LevandoskiLA, et al.Plasma pancreatic-polypeptide response to insulin-induced hypoglycemia as a marker for defective glucose counterregulation in insulin-dependent diabetes-mellitus. Diabetes, 1985; 34(9):870–875.
58.
HoeldtkeRD, BodenG. Epinephrine secretion, hypoglycemia unawareness, and diabetic autonomic neuropathy. Ann Intern Med, 1994; 120(6):512–517.
59.
RyderRE, OwensDR, HayesTM, et al.Unawareness of hypoglycaemia and inadequate hypoglycaemic counterregulation: No causal relation with diabetic autonomic neuropathy. BMJ, 1990; 301:783–787.
60.
FlattAJS, LittleSA, SpeightJ, et al.Predictors of recurrent severe hypoglycemia in adults with type 1 diabetes and impaired awareness of hypoglycemia during the HypoCOMPaSS study. Diabetes Care, 2020; 43(1):44–52.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
